{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T02:07:04Z","timestamp":1769566024603,"version":"3.49.0"},"reference-count":46,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"BARDA","doi-asserted-by":"publisher","award":["75A50120C00131"],"award-info":[{"award-number":["75A50120C00131"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH","doi-asserted-by":"publisher","award":["75N93020C00053"],"award-info":[{"award-number":["75N93020C00053"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: A novel platform to produce whole-virion vaccines using riboflavin and ultraviolet (UV) light for photochemical inactivation has been developed. We previously reported on the potential for this platform to produce a safe and effective inactivated whole-virion SARS-CoV-2 vaccine. Feasibility studies used a hamster infection challenge model to explore the effects of route of administration and adjuvants on immune responses elicited by the vaccine candidate. Here, we utilized the same animal model to evaluate the dose response to the vaccine candidate in combination with the adjuvant CpG1018. Methods: A pilot batch of the vaccine candidate was produced at a contract development and manufacturing organization (CDMO) for use in this study. A two-dose intramuscular regimen at three antigen concentrations formulated with CpG1018 adjuvant was assessed against a live SARS-CoV-2 (USA-WA-1\/2020) challenge. Results: The vaccine elicited dose-dependent neutralizing antibody responses, with peak PRNT50 titers exceeding 1:5120. Vaccination significantly reduced lung viral burden and mitigated pulmonary pathology compared to controls. Antibodies persisted up to 154 days post-vaccination and neutralized Delta and Omicron (Jn.1) variants but showed limited activity against XBB.1.5. Flow cytometry revealed enhanced CD4+ Th1-biased responses in higher-dose groups. Conclusions: These findings demonstrate the protective efficacy of the SolaVAX SARS-CoV-2 vaccine candidate and support further evaluation of this vaccine production platform.<\/jats:p>","DOI":"10.3390\/vaccines14020121","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:35:42Z","timestamp":1769513742000},"page":"121","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose-Dependent Efficacy of a Riboflavin and Ultraviolet Light-Inactivated Whole-Virion SARS-CoV-2 Vaccine in a Hamster Infection Challenge Model"],"prefix":"10.3390","volume":"14","author":[{"given":"Noelia","family":"Altina","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-6015","authenticated-orcid":false,"given":"Izabela K.","family":"Ragan","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly A.","family":"Arnett","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Socks","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arielle","family":"Glass","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5101-1311","authenticated-orcid":false,"given":"Taru S.","family":"Dutt","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Obregon-Henao","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mac","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Bowen","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Kruh-Garcia","sequence":"additional","affiliation":[{"name":"BioMARC, Infectious Disease Research Center, Colorado State University, Fort Collins, CO 80521, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darragh","family":"Heaslip","sequence":"additional","affiliation":[{"name":"BioMARC, Infectious Disease Research Center, Colorado State University, Fort Collins, CO 80521, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-7987","authenticated-orcid":false,"given":"Susan","family":"Yonemura","sequence":"additional","affiliation":[{"name":"Independent Researcher, Fort Collins, CO 80526, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4249-9650","authenticated-orcid":false,"given":"Marcela","family":"Henao-Tamayo","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-4571","authenticated-orcid":false,"given":"Raymond P.","family":"Goodrich","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3201\/eid2108.141086","article-title":"Development of Framework for Assessing Influenza Virus Pandemic Risk","volume":"21","author":"Trock","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2006.01194.x","article-title":"Emerging Viral Diseases and Infectious Disease Risks","volume":"12","author":"Tapper","year":"2006","journal-title":"Haemophilia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41590-017-0007-9","article-title":"Emerging Viral Diseases from a Vaccinology Perspective: Preparing for the next Pandemic","volume":"19","author":"Graham","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_4","first-page":"159","article-title":"Emerging and Re-Emerging Infectious Diseases: A Potential Pandemic Threat","volume":"5","author":"Zyga","year":"2011","journal-title":"Health Sci. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1473-3099(14)70846-1","article-title":"Emerging Infectious Diseases and Pandemic Potential: Status Quo and Reducing Risk of Global Spread","volume":"14","author":"McCloskey","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cell.2020.08.021","article-title":"Emerging Pandemic Diseases: How We Got to COVID-19","volume":"182","author":"Morens","year":"2020","journal-title":"Cell"},{"key":"ref_7","unstructured":"(2025, December 10). Global Preparedness Monitoring Board A World at Risk\u2014GPMB 2019 Annual Report. Available online: https:\/\/gpmb.org\/reports\/m\/item\/2019-a-world-at-risk."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41577-021-00522-1","article-title":"The First 12 Months of COVID-19: A Timeline of Immunological Insights","volume":"21","author":"Carvalho","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","first-page":"1","article-title":"The Impacts of the Coronavirus on the Economy of the United States","volume":"5","author":"Walmsley","year":"2021","journal-title":"Econ. Dis. Clim. Chang."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1080\/13696998.2021.1965732","article-title":"Economic Value of Vaccines to Address the COVID-19 Pandemic: A U.S. Cost-Effectiveness and Budget Impact Analysis","volume":"24","author":"Padula","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1001\/jama.2020.19759","article-title":"The COVID-19 Pandemic and the $16 Trillion Virus","volume":"324","author":"Cutler","year":"2020","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.plas.2021.100019","article-title":"Operation Warp Speed: Projects Responding to the COVID-19 Pandemic","volume":"2","author":"Winch","year":"2021","journal-title":"Proj. Leadersh. Soc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.21140\/mcuj.20221301007","article-title":"Operation Warp Speed and the Countermeasures Acceleration Group\u2014A Twenty-First Century Manhattan Project: Preliminary Observations on the U.S. Department of Defense\u2019s Role in the Supply, Production, and Distribution of COVID-19 Vaccines and Therapeutics","volume":"13","author":"Hall","year":"2022","journal-title":"J. Adv. Mil. Stud."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.11622\/smedj.2019002","article-title":"Jonas Salk (1914\u20131995): A Vaccine against Polio","volume":"60","author":"Tan","year":"2019","journal-title":"Singap. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kozak, M., and Hu, J. (2023). The Integrated Consideration of Vaccine Platforms, Adjuvants, and Delivery Routes for Successful Vaccine Development. Vaccines, 11.","DOI":"10.3390\/vaccines11030695"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Nunnally, B.K., Turula, V.E., and Sitrin, R.D. (2015). Inactivated Viral Vaccines. Vaccine Analysis: Strategies, Principles, and Control, Springer.","DOI":"10.1007\/978-3-662-45024-6"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Guedes-da-Silva, F.H., Roncaglia-Pereira, V.A., Torres, S., Garc\u00eda, M.C.E., Viana, K.F., Silva, J.L., Oliveira, A.C., and Gomes, A.M.O. (2025). Antiviral Inactivated Vaccines: Looking to the Past to Face the Future\u2014A Narrative Review. Vaccines, 13.","DOI":"10.3390\/vaccines13111140"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Elveborg, S., Monteil, V.M., and Mirazimi, A. (2022). Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes. Pathogens, 11.","DOI":"10.3390\/pathogens11020271"},{"key":"ref_20","unstructured":"(2025, December 26). ThermoFisher Scientific Safety Data Sheet\u2014Beta-Propiolactone (CAS No. 57-57-8). Available online: https:\/\/www.fishersci.com\/store\/msds?partNumber=AAB2319703&productDescription=BETA-PROPIOLACTONE+97%25+1G&vendorId=VN00024248&countryCode=US&language=en."},{"key":"ref_21","unstructured":"(2025, December 10). Sigma-Aldrich Safety Data Sheet\u2014Formalin (CAS No. 50-00-0). Available online: https:\/\/www.sigmaaldrich.com\/US\/en\/sds\/sial\/252549?srsltid=AfmBOorJhs1SaHvzTklouisMZ_NRj1_AuOVvxCHldbu4w29nAlHaeviz."},{"key":"ref_22","first-page":"15","article-title":"Riboflavin and UV-Light Based Pathogen Reduction: Extent and Consequence of DNA Damage at the Molecular Level","volume":"80","author":"Kumar","year":"2004","journal-title":"Photochem. Photobiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ragan, I., Hartson, L., Pidcoke, H., Bowen, R., and Goodrich, R. (2020). Pathogen Reduction of SARS-CoV-2 Virus in Plasma and Whole Blood Using Riboflavin and UV Light. PLoS ONE, 15.","DOI":"10.1101\/2020.05.03.074971"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/vox.12937","article-title":"Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 in Plasma and Platelet Products Using a Riboflavin and Ultraviolet Light-based Photochemical Treatment","volume":"115","author":"Keil","year":"2020","journal-title":"Vox Sang."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/vox.13108","article-title":"Preservation of Neutralizing Antibody Function in COVID-19 Convalescent Plasma Treated Using a Riboflavin and Ultraviolet Light-based Pathogen Reduction Technology","volume":"116","author":"Yonemura","year":"2021","journal-title":"Vox Sang."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ragan, I.K., Hartson, L.M., Dutt, T.S., Obregon-Henao, A., Maison, R.M., Gordy, P., Fox, A., Karger, B.R., Cross, S.T., and Kapuscinski, M.L. (2021). A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model. Vaccines, 9.","DOI":"10.3390\/vaccines9040340"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1177\/1060028020962050","article-title":"Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant","volume":"55","author":"Champion","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dutt, T.S., Spencer, J.S., Karger, B.R., Fox, A., Obregon-Henao, A., Podell, B.K., Anderson, G.B., and Henao-Tamayo, M. (2024). ELISA-R: An R-Based Method for Robust ELISA Data Analysis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1427526"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1165\/rcmb.2020-0280LE","article-title":"Standardization of Reporting Criteria for Lung Pathology in SARS-CoV-2\u2013Infected Hamsters: What Matters?","volume":"63","author":"Gruber","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic SARS-CoV-2 Infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41541-024-00888-y","article-title":"Direct Comparison of SARS-CoV-2 Variant Specific Neutralizing Antibodies in Human and Hamster Sera","volume":"9","author":"Netzl","year":"2024","journal-title":"npj Vaccines"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"eadl1722","DOI":"10.1126\/scitranslmed.adl1722","article-title":"Comparative Analysis of SARS-CoV-2 Neutralization Titers Reveals Consistency between Human and Animal Model Serum and across Assays","volume":"16","author":"Wilks","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e00948-24","DOI":"10.1128\/jvi.00948-24","article-title":"Human and Hamster Sera Correlate Well in Identifying Antigenic Drift among SARS-CoV-2 Variants, Including JN.1","volume":"98","author":"Wang","year":"2024","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2021.10.007","article-title":"Syrian Hamsters as a Model of Lung Injury with SARS-CoV-2 Infection: Pathologic, Physiologic, and Detailed Molecular Profiling","volume":"240","author":"Bednash","year":"2022","journal-title":"Transl. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 Vaccines Strategies: A Comprehensive Review of Phase 3 Candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"npj Vaccines"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev-med-042420-113212","article-title":"Whole Inactivated Virus and Protein-Based COVID-19 Vaccines","volume":"73","author":"Hotez","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100099","DOI":"10.1016\/j.indenv.2025.100099","article-title":"Ultraviolet Germicidal Irradiation: Advances in Viral Inactivation and Vaccine Development","volume":"2","author":"Glover","year":"2025","journal-title":"Indoor Environ."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"13804","DOI":"10.1038\/s41598-021-93231-7","article-title":"UVC Disinfects SARS-CoV-2 by Induction of Viral Genome Damage without Apparent Effects on Viral Morphology and Proteins","volume":"11","author":"Lo","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e11132","DOI":"10.1016\/j.heliyon.2022.e11132","article-title":"Irradiation of UVC LED at 277 Nm Inactivates Coronaviruses in Association to Photodegradation of Spike Protein","volume":"8","author":"Ong","year":"2022","journal-title":"Heliyon"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00705-022-05530-7","article-title":"Immunogenic Properties of SARS-CoV-2 Inactivated by Ultraviolet Light","volume":"167","author":"Gracheva","year":"2022","journal-title":"Arch. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1038\/s41598-021-85425-w","article-title":"UV-C Irradiation Is Highly Effective in Inactivating SARS-CoV-2 Replication","volume":"11","author":"Biasin","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abd4251","article-title":"Distinct Conformational States of SARS-CoV-2 Spike Protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"112443","DOI":"10.1016\/j.celrep.2023.112443","article-title":"Enhanced Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1, and CA.3.1 Variants","volume":"42","author":"Qu","year":"2023","journal-title":"Cell Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1002\/mco2.239","article-title":"The Rapid Rise of SARS-CoV-2 Omicron Subvariants with Immune Evasion Properties: XBB.1.5 and BQ.1.1 Subvariants","volume":"4","author":"Ao","year":"2023","journal-title":"MedComm"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/JS9.0000000000000246","article-title":"The SARS-CoV-2 Omicron Recombinant Subvariants XBB, XBB.1, and XBB.1.5 Are Expanding Rapidly with Unique Mutations, Antibody Evasion, and Immune Escape Properties\u2014An Alarming Global Threat of a Surge in COVID-19 Cases Again?","volume":"109","author":"Chakraborty","year":"2023","journal-title":"Int. J. Surg."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/2\/121\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:41:09Z","timestamp":1769514069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/2\/121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["vaccines14020121"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14020121","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}